Elanco Animal Health Inc quarterly report, Q3 FY2018

Business context and reporting period

Elanco Animal Health Incorporated is a global animal-health company serving companion and food animals in more than 90 countries. This Form 10-Q covers the quarter and nine months ended September 30, 2018, compared with the corresponding 2017 periods. Elanco completed its IPO and separation from Eli Lilly on September 24, 2018; Lilly retained approximately 80.2% of Elanco’s shares at quarter-end.

Financial performance and position

At September 30, 2018, cash and cash equivalents were $300.0 million, restricted cash was $634.9 million, and total current assets and liabilities were $2,703.7 million and $1,245.4 million, respectively. Restricted cash was matched by a $634.9 million payable to Lilly and should not be treated as freely available liquidity. Long-term debt was $2,478.5 million; the $750 million revolving facility had no borrowings outstanding. Capital expenditures were $74.3 million for the first nine months.

Material changes versus prior comparable periods

• Q3 revenue rose 9%; management attributed the increase to 7% higher volume and 4% higher realized prices, partly offset by a 2% adverse foreign-exchange effect. Nine-month revenue rose 6%, reflecting price and volume growth and a favorable currency impact.
• Q3 net income improved from a loss to profit. For the nine-month period, the loss-to-profit improvement reflected stronger revenue and substantially lower impairment, restructuring and special charges: $82.8 million versus $189.3 million.
• Q3 cost of sales declined 2% despite higher revenue, lifting gross margin. Nine-month cost of sales increased 7%, including inventory write-offs, while gross margin remained approximately 49%.
• Companion Animal Disease Prevention was a leading growth category: revenue increased 34% in Q3 and 16% for nine months. Companion Animal Therapeutics increased 27% and 16%, respectively. Strategic Exits revenue declined 42% in both periods.
• Operating cash flow more than doubled year over year for nine months. Investing cash use fell markedly from 2017, which included $882.1 million for an acquisition.

Outlook, management commentary, risks and unusual items

• Management said cash on hand, operating cash flow and financing arrangements should cover needs for at least the next 12 months. The filing provides no specific revenue or earnings guidance.
• Elanco estimated $240 million to $290 million of costs to establish standalone functions and systems; some will be capitalized and the remainder expensed. The company also expected temporary duplicative costs as it replaces Lilly-provided services. Annual interest expense on new borrowings was estimated at approximately $110 million.
• Elanco issued $2.0 billion of senior notes and borrowed $500 million under a term facility. The term facility has a variable rate, 3.50% at September 30, 2018; the company reported compliance with debt covenants.
• Unusual charges included $63.9 million of noncash asset impairments for the first nine months, primarily related to product rationalization, a U.S. manufacturing-facility disposal decision and suspension of Imrestor commercial activity. The company also recorded $38.6 million of inventory write-offs, primarily related to Imrestor.
• Key risks include competition and generics, product safety or efficacy concerns, regulatory and market changes regarding antibiotics, R&D and launch execution, foreign-exchange movements, customer and distributor consolidation, and standalone-company costs. A hypothetical 10% adverse currency movement was estimated to reduce nine-month net income by about $12 million.
• The filing reported no litigation liabilities because no claims were considered both probable and estimable. The company had not completed its accounting for the 2017 U.S. tax law and noted that resulting updates could materially change provisional amounts or the estimated tax rate.

Important facts for investors to verify

• Whether revenue growth, particularly in companion-animal products, persists after accounting for prior-year stock-outs, purchasing patterns, pricing and strategic exits.
• Actual standalone transition costs versus the $240 million to $290 million estimate, and whether replacing Lilly services changes ongoing costs.
• Debt-service capacity and covenant headroom, including the impact of variable interest rates and restricted cash/payables to Lilly on usable liquidity.
• Further impairment, inventory write-offs or commercial effects from product rationalization and the Imrestor suspension.
• Final tax accounting, the effect of the tax matters agreement, and any eventual Lilly distribution of its retained Elanco shares.
• The filing notes an immaterial $10.5 million correction to the December 2017 sales-rebate accrual; investors may verify its presentation and related rebate-estimation exposure.